Uncovering Minimally Invasive Biomarkers in the Extracellular Matrix That Accurately Reflect Pulmonary Conditions
Time: 12:15 pm
day: Day One Track B AM
Details:
• Examining the desperate need for reliable biomarkers for assessing drug efficacy beyond just clinical endpoints like FVC decline
• Promise of AI for unbiased and quantitative measures of disease progression and the potential use as a surrogate endpoint
• Exploring multi-modal biomarkers, combining blood, imaging, and beyond to paint a more complete picture of disease progression